Canaloplasty an option after failed trabeculectomy

Article

If initial trabeculectomy has failed, canaloplasty can be an option, according to Dr Brusini

A perfectly performed trabeculectomy can fail to lower intraocular pressure (IOP), even if mitomycin C has been used, because of pre-existing conjunctival scarring. If this is the case, a second trabeculectomy will seldom provide adequate IOP control for precisely the same reasons that caused the initial surgical failure. Typically, either the implant of a tube or a diode laser cyclophotocoagulation would be recommended as the next step for treating these cases, but both of these options entail several possible serious complications. Therefore, an alternative surgical option for treating glaucoma is essential.

Although it is normally indicated for eyes that have not undergone previous filtrating surgery for glaucoma, canaloplasty is a viable alternative surgical option for a select number of eyes in which postoperative gonioscopic examination shows that the initial 'trabeculectomy' had been performed anterior to the trabecular structures - in other words, had in fact been a sclero-keratectomy - and that Schlemm's canal had been left intact. This scenario is now seen more frequently, especially in eyes in which an emport-piece trabeculectomy is associated with a one-site phacoemulsification.

As canaloplasty is not dependent on conjunctiva status for proper functioning, it is an appropriate treatment in these eyes, particularly in cases where IOP remains elevated despite maximum tolerated medical therapy and therefore further surgery is indicated.

"A mandatory prerequisite for this surgery is an apparently intact Schlemm's canal at gonioscopy," he notes. "The presence of peripheral anterior synechiae or previous argon laser trabeculoplasty can affect the success of canaloplasty, making it difficult or sometimes impossible to perform cannulation; however, these should not be considered as absolute contraindications for this procedure."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.